Tsingke's Gambit: Orchestrating China's Nucleic Acid Revolution

SHANGHAI, China – June 30, 2026 – When Tsingke Biotech gathered a roster of industry experts at a Shanghai hotel, it was ostensibly to discuss the future of oligonucleotide drugs. Yet, the event was far more than a simple industry salon. It was a calculated demonstration of Tsingke's ambition to become the central nervous system for China's burgeoning nucleic acid therapeutics sector, a field undergoing a seismic shift from imitation to indigenous innovation.

As stakeholders from academia, biopharma, and investment circles convened, the underlying narrative became clear: the race to develop next-generation genetic medicines is not just about individual scientific breakthroughs, but about building an integrated ecosystem. Tsingke, a synthetic biology specialist with a mission to build "the world's great gene factory," is positioning itself not merely as a participant, but as the orchestrator of that ecosystem.

From Adoption to Innovation: A National Pivot

Opening the event, Tsingke Biotech CEO Shijin Ma articulated a sentiment that resonates with China's broader national strategy. He noted that the country's small nucleic acid industry is moving beyond simple technology adoption and entering a new phase of innovation-driven growth. This transition is no accident; it is the direct result of strategic government support under initiatives like the 14th and 15th Five-Year Plans, which prioritize biomanufacturing and biotechnology as pillars of future economic strength.

"Open collaboration has become increasingly important as the industry advances," Ma stated, emphasizing that progress hinges on coordinated innovation across the entire value chain. His words reflect a strategic necessity. While China's biopharma R&D spending has skyrocketed, the path to global leadership requires more than capital. It demands the integration of disparate elements: novel science, scalable manufacturing (CMC), sophisticated regulatory strategy, and capital market savvy. By hosting the salon, Tsingke signaled its intent to be the platform where these elements converge.

This ambition places Tsingke in a competitive, yet rapidly expanding market. The company is vying for position against established domestic players like Genscript and global contract development and manufacturing organizations (CDMOs) like WuXi AppTec. However, Tsingke's strategy appears focused on providing a deeply integrated, full-lifecycle platform—from AI-assisted sequence design and synthesis to IND-enabling CMC studies—aimed at empowering the wave of smaller, innovation-focused biotechs that are the engine of China's new R&D landscape.

Cracking the Code of Delivery and Regulation

The scientific discussions at the salon underscored the formidable challenges that remain in the field. A key theme was the push to solve one of the holy grails of oligonucleotide therapy: effective drug delivery to tissues beyond the liver. Dr. Jun Bai of Haichang Biotech highlighted advances in GalNAc conjugates and antibody-oligonucleotide conjugates (AOCs), which aim to guide these genetic medicines to new targets like adipose tissue or the kidneys. Similarly, Professor Qixian Chen, Tsingke's Chief Scientist, detailed novel approaches for overcoming intracellular barriers to deliver therapies to the central nervous system and tumors.

These scientific frontiers are matched by a complex and evolving regulatory landscape. The presence of Dr. Yaning Wang, a former FDA director and now a chief scientific advisor to Tsingke, was a telling inclusion. His analysis of FDA approval cases provided a masterclass in navigating the world's most stringent regulatory body. This is critically important as China's own National Medical Products Administration (NMPA) modernizes its framework. With the CDE's 2025 draft guidelines for oligonucleotide drugs and the formalization of expedited review pathways, China is aligning with global standards and even accepting overseas clinical data to speed up approvals.

For drug developers, this harmonization is a double-edged sword: it creates clearer pathways but also demands a higher standard of evidence. A company like Tsingke, which offers both deep CMC expertise—as detailed by Dr. Chengjiang Zhao of Youjia Biomedical—and high-level regulatory strategy, is providing a crucial service. It is helping clients generate the robust data packages required to satisfy regulators in both Beijing and Washington D.C., effectively de-risking a critical phase of development.

The Dual Engines: AI and Collaboration

If collaboration is the external engine driving the industry forward, an internal engine of technological innovation is being supercharged by artificial intelligence. The roundtable discussion that concluded the salon reinforced that competitiveness now depends on integrating scientific innovation with manufacturing capabilities and regulatory expertise. Tsingke is taking this a step further by weaving AI into the fabric of its operations.

The company is actively exploring AI for sequence design, candidate screening, and process optimization. This is not a futuristic talking point; it is a core component of its "gene factory" concept. By using AI to predict the most effective and least toxic oligonucleotide sequences and to optimize manufacturing protocols, Tsingke aims to dramatically shorten development timelines and improve the probability of success. This AI-driven biomanufacturing ecosystem bridges the gap between digital design and GMP-grade production, a crucial advantage in a field where speed and efficiency are paramount.

Tsingke's recent salon was a snapshot of a company and a country in rapid transition. It showcased a firm that understands the modern biopharma landscape is a team sport, requiring open platforms and deep partnerships. By assembling the key players, showcasing solutions to the industry's toughest scientific and regulatory problems, and underpinning it all with a powerful technology platform, Tsingke Biotech is making a compelling case that it is ready to supply the picks and shovels—and perhaps even draw the maps—for China's gold rush in nucleic acid medicine.